Evidence map›Paper›PMID 36048313›Full record

ArticleJournal of cancer survivorship : research and practice2023

Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.

Saiko Kurosawa, Takuhiro Yamaguchi, Ayako Mori, Tomoko Matsuura, Masayoshi Masuko, Makoto Murata, Haruko Tashiro, Shinichi Kako, Atsushi Satake, Maki Hagihara and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 18 institutions in 1 country.

Saiko KurosawaDepartment of Oncology, Ina Central Hospital, 1313-1 Koshiro-kubo, Ina, Nagano, 396-8555, Japan. skurosaw@inahp.jp.ORCID http://orcid.org/0000-0002-6819-9381
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ayako MoriNursing Division, National Cancer Center Hospital, Tokyo, Japan.
Tomoko MatsuuraNursing Division, National Cancer Center Hospital, Tokyo, Japan.
Masayoshi MasukoDepartment of Hematopoietic Cell Therapy, Niigata University Medical and Dental Hospital, Niigata, Japan.
Makoto MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Haruko TashiroDepartment of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan.
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Atsushi SatakeFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Maki HagiharaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Takeshi SaitoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kumiko KagawaDepartment of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Yayoi MatsuoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Hidehiro ItonagaDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kensuke NaitoDepartment of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
Miyako TakahashiJapan Cancer Survivorship Network, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Jikei University School of Medicine · JPFukuoka Hospital · JPHamamatsu Medical Center · JPHamanomachi Hospital · JPJapanese Red Cross Society Kyoto Daini Hospital · JPJichi Medical University · JPKansai Medical University · JPKubota (Japan) · JPNagasaki University Hospital · JPNagoya University · JPNiigata University Medical and Dental Hospital · JPNippon Medical School · JPSapporo Hokuyu Hospital · JPTeikyo University · JPTohoku University · JPTokushima University · JPTokyo National Hospital · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough rather favorable probabilities of return to work have been reported after allogeneic hematopoietic cell transplantation (allo-HCT), survivors often have difficulty continuing to work because of their immunocompromised status and diverse late effects after allo-HCT. We evaluated the incidence of and risk factors for recurrent sick leave in allo-HCT survivors after they initially returned to work.

methodsWe targeted allo-HCT survivors who were employed at diagnosis, aged 20-64 at survey, and survived for ≥ 2 years without relapse. Of the 1904 survivors who were informed of the study, 1148 returned the questionnaire (60%), and 1048 eligible participants were included in the overall analysis. In the present study that considered recurrent sick leave after return to work, we targeted 896 participants who returned to work at least once after allo-HCT. Participants stated if they had recurrent sick leave after returning to work and its reasons, as well as associated patient-, HCT/HCT center-, and work-related factors and clinical events after allo-HCT. A logistic regression analysis was conducted to explore correlated factors for recurrent sick leave.

resultsIn survivors who returned to work, 30% required recurrent sick leave. The most frequent causes of recurrent leave were physical issues (72%), and analysis of free descriptions demonstrated that these were mainly associated with graft-versus-host disease, infection, or readmission. Other reasons included work-related issues such as gap between physical and working conditions. Multivariate analysis showed that cord blood transplantation, longer employment duration, and counseling from healthcare professionals were associated with a lower risk of recurrent leave. Readmission, immunosuppressant use, and symptoms involving the respiratory system, gut, and joints and muscles were associated with a higher risk.

conclusionsOur results drawn from a large cohort study should help healthcare professionals identify and assist at-risk patients. Multi-professional teams that provide continuous support and effective communication with the workplace are necessary to improve long-term outcomes after allo-HCT. IMPLICATIONS FOR CANCER SURVIVORS: In order to continue working after the initial return to work, it is important to receive counseling from healthcare professionals and obtain reasonable accommodation from workplace.

Indexed as

Cancer SurvivorsHematopoietic Stem Cell TransplantationCohort StudiesEmploymentHumansIncidenceReturn to WorkSick LeaveSurvivorsAllogeneic hematopoietic cell transplantationRecurrent sick leaveResignationReturn to workSurvivorship

Identifiers

PMID36048313
OpenAlexW4294011710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.